Research
Energy balance
Higher weight loss was associated with a lower hazard of discontinuation for both patients with and without type 2 diabetes.
Encouraging weight loss may improve adherence to GLP-1 RA therapy.
StrongSupportsmedium confidence
Higher weight loss (1% reduction in weight from baseline was associated with a 3.1% [95% CI, 2.9%-3.2%] lower hazard of discontinuation for patients with type 2 diabetes and a 3.3% [95% CI, 3.2%-3.5%] lower hazard of discontinuation for patients without type 2 diabetes).
Why this rating
Based on the large cohort study design.
Source
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity
Patricia J. Rodriguez et al. · JAMA Network Open · 2025
cohort · n=125474Cited 236×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →